Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
a new anti-diabetic drug
is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease
The low-affinity site accounts for the residual 75% of binding (IC50) 790 nM and represents binding to the R1a sites
Almstead ZY
It can cause the symptoms of diarrhoea and myelosuppression experienced by ~25% of the patients administered irinotecan
Tebanicline hydrochloride Size:Contact [email protected] for quotation a new anti-diabetic drugTebanicline hydrochloride (ABT594 hydrochloride) is a nAChR modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to 42 neuronal nAChRs with a Ki of 37 pM. Tebanicline is a novel, potent cholinergic nAChR ligand with analgesic properties that shows preferential selectivity for neuronal nAChRs. It inhibits the binding of cytisine to 42 neuronal nAChRs with a Ki of 37 pM. Functionally, tebanicline is an agonist.